The Pharmacokinetic Interaction of Tirabrutinib with Voriconazole, Itraconazole, and Fluconazole in SD Rats by UPLC-MS/MS


Cite item

Full Text

Abstract

Background:Tirabrutinib is an orally effective, approved, and highly selective second-generation Bruton's tyrosine kinase (BTK) inhibitor for the treatment of recurrent or refractory primary central nervous system lymphoma (PCNSL).

Objective:This study aimed to develop an ultra-high performance liquid chromatography- tandem mass spectrometry (UPLC-MS/MS) method for the determination of tirabrutinib concentration in rat plasma, where zanubrutinib was used as an internal standard (IS). This method was also applied to study whether tirabrutinib would interact with voriconazole, itraconazole, and fluconazole in rats, providing a reference value for clinical medication guidance.

Methods:In the current study, the organic solvent protein precipitation method was used to treat plasma samples, which is simple and reproducible. Tirabrutinib (m/z 455.32 → 320.21) and zanubrutinib (m/z 472.13 → 455.04) were separated on a Waters Acquity BEH C18 column (2.1 × 50 mm, 1.7 µm) and detected by multiple reaction monitoring (MRM) in positive ionization mode.

Results:The method showed good linearity in the range of 5−3000 ng/mL for tirabrutinib with the lower limit of quantification (LLOQ) of 5 ng/mL. The recovery and matrix effects were 85.7-91.0% and 102.0-113.3%, respectively. The accuracy, precision, stability, and carry-over effect were also acceptable. The method could also be used for determining the pharmacokinetic interaction of tirabrutinib in rats. The results showed AUC0→∞ of tirabrutinib to be increased by 139.3% and 83.9% in the presence of voriconazole and fluconazole, respectively, while itraconazole had little effect.

Conclusion:It is necessary to monitor the concentration of tirabrutinib in patients when it is combined with voriconazole and fluconazole to achieve a better therapeutic effect and reduce the risk of adverse reaction. Further research should be conducted in the future.

About the authors

Mengming Xia

The Affiliated Lihuili Hospital, Ningbo University

Email: info@benthamscience.net

Ya-Nan Liu

, The First Affiliated Hospital of Wenzhou Medical University

Email: info@benthamscience.net

Jie Chen

, The First Affiliated Hospital of Wenzhou Medical University

Email: info@benthamscience.net

Ren-Ai Xu

, The First Affiliated Hospital of Wenzhou Medical University

Author for correspondence.
Email: info@benthamscience.net

Gexin Dai

, The First Affiliated Hospital of Wenzhou Medical University

Author for correspondence.
Email: info@benthamscience.net

References

  1. Pal Singh, S.; Dammeijer, F.; Hendriks, R.W. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol. Cancer, 2018, 17(1), 57. doi: 10.1186/s12943-018-0779-z PMID: 29455639
  2. Liclican, A.; Serafini, L.; Xing, W.; Czerwieniec, G.; Steiner, B.; Wang, T.; Brendza, K.M.; Lutz, J.D.; Keegan, K.S.; Ray, A.S.; Schultz, B.E.; Sakowicz, R.; Feng, J.Y. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton’s tyrosine kinase reveals differences in on : And off : Target inhibition. Biochim. Biophys. Acta, Gen. Subj., 2020, 1864(4), 129531. doi: 10.1016/j.bbagen.2020.129531 PMID: 31953125
  3. Castillo, J.J.; Treon, S.P.; Davids, M.S. Inhibition of the bruton tyrosine kinase pathway in B-cell lymphoproliferative disorders. Cancer J., 2016, 22(1), 34-39. doi: 10.1097/PPO.0000000000000170 PMID: 26841015
  4. Küppers, R. Mechanisms of B-cell lymphoma pathogenesis. Nat. Rev. Cancer, 2005, 5(4), 251-262. doi: 10.1038/nrc1589 PMID: 15803153
  5. Liu, X.J.; Xu-Liu; Pang, X.J.; -Ying Yuan, X.; Yu, G.X.; Li, Y.R.; Guan, Y.F.; Zhang, Y.B.; Song, J.; Zhang, Q.R.; Zhang, S.Y. Progress in the development of small molecular inhibitors of the Bruton’s tyrosine kinase (BTK) as a promising cancer therapy. Bioorg. Med. Chem., 2021, 47, 116358. doi: 10.1016/j.bmc.2021.116358 PMID: 34479103
  6. Dhillon, S. Tirabrutinib: First approval. Drugs, 2020, 80(8), 835-840. doi: 10.1007/s40265-020-01318-8 PMID: 32382949
  7. Pharmaceutical, O. ONO Receives a Manufacturing and Marketing Approval for Velexbru® Tablet 80mg, a BTK inhibitor, for Treatment of Recurrent or Refractory Primary Central Nervous System Lymphoma in Japan; Ono Pharmaceutical Co., Ltd, 2020.
  8. Holdhoff, M.; Mrugala, M.M.; Grommes, C.; Kaley, T.J.; Swinnen, L.J.; Perez-Heydrich, C.; Nayak, L. Challenges in the treatment of newly diagnosed and recurrent primary central nervous system lymphoma. J. Natl. Compr. Cancer. Netw., 2020, 18(11), 1571-1578. doi: 10.6004/jnccn.2020.7667 PMID: 33152700
  9. Grommes, C.; DeAngelis, L.M.; Primary, C.N.S. Primary CNS Lymphoma. J. Clin. Oncol., 2017, 35(21), 2410-2418. doi: 10.1200/JCO.2017.72.7602 PMID: 28640701
  10. Bashir, M.K.; Mustafa, Y.F.; Oglah, M.K. Synthesis and antitumor activity of new multifunctional coumarins. Periód. Tchê Quím., 2020, 17(36), 871-883. doi: 10.52571/PTQ.v17.n36.2020.886_Periodico36_pgs_871_883.pdf
  11. Langner-Lemercier, S.; Houillier, C.; Soussain, C.; Ghesquières, H.; Chinot, O.; Taillandier, L.; Soubeyran, P.; Lamy, T.; Morschhauser, F.; Benouaich-Amiel, A.; Ahle, G.; Moles-Moreau, M.P.; Moluçon-Chabrot, C.; Bourquard, P.; Damaj, G.; Jardin, F.; Larrieu, D.; Gyan, E.; Gressin, R.; Jaccard, A.; Choquet, S.; Brion, A.; Casasnovas, O.; Colin, P.; Reman, O.; Tempescul, A.; Marolleau, J.P.; Fabbro, M.; Naudet, F.; Hoang-Xuan, K.; Houot, R. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro-oncol., 2016, 18(9), 1297-1303. doi: 10.1093/neuonc/now033 PMID: 26951382
  12. Narita, Y.; Nagane, M.; Mishima, K.; Terui, Y.; Arakawa, Y.; Yonezawa, H.; Asai, K.; Fukuhara, N.; Sugiyama, K.; Shinojima, N.; Kitagawa, J.; Aoi, A.; Nishikawa, R. Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro-oncol., 2021, 23(1), 122-133. doi: 10.1093/neuonc/noaa145 PMID: 32583848
  13. Pagano, L.; Caira, M.; Candoni, A.; Aversa, F.; Castagnola, C.; Caramatti, C.; Cattaneo, C.; Delia, M.; De Paolis, M.R.; Di Blasi, R.; Di Caprio, L.; Fanci, R.; Garzia, M.; Martino, B.; Melillo, L.; Mitra, M.E.; Nadali, G.; Nosari, A.; Picardi, M.; Potenza, L.; Salutari, P.; Trecarichi, E.M.; Tumbarello, M.; Verga, L.; Vianelli, N.; Busca, A.; Group, S. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin. Infect. Dis., 2012, 55(11), 1515-1521. doi: 10.1093/cid/cis773 PMID: 22955439
  14. Ono Pharmaceutical Co., L; Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, 2020.
  15. Administration, U.F.a.D. Bioanalytical Method Validation Guidance for Industry. 2018. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers